Abstract #0149

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Early Therapy Evaluation of Combined Anti-EGFR Antibody and Irinotecan in Orthotopic Pancreatic Tumor Xenografts

Hyunki Kim¹, Karri Folks¹, Lingling Guo², Jeffery Sellers³, Naomi Fineberg⁴, Cecil Stockard³, William Grizzle⁵, Donald Buchsbaum⁶, Desiree Morgan¹, James George², Kurt Zinn¹

¹Radiology, University of Alabama at Birmingham, Birmingham, AL, United States; ²Surgery, University of Alabama at Birmingham, Birmingham, AL, United States; ³Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States; ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, United States; ⁵Pathology, University of Alabama at Birmingham, Birmingham, AL, United States; ⁶Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States

This study evaluated DCE-MRI as an early prognostic tool for effective anti-EGFR therapy with/without concurrent chemotherapy in an orthotopic pancreatic-cancer murine model, and developed a novel timing-independent DCE-MRI biomarker for early therapy assessment, based on characterization of non-linear tumor response observed during serial imaging.